¥3.37 +0.08   ( +2.43%)
前日收盘:3.29 当日成交量(股):1.55万 当日最高:3.65 总股本:825.30万
当日开盘:3.65 当日成交额(元):5.19万 当日最低:3.15 流通股本:
市盈率(动/静):0/0 市净率:1.42 市销率:0 总市值:2716.82万
52周最高:14.85 52周最低:2.55 转让方式: 单位:美元
$Citius Pharmaceuticals(CTXR)$
  • 还可以输入
  • 20016

Citius Pharmaceuticals(CTXR) 09月22日 06时15分

查看全文

Citius Pharmaceuticals(CTXR) 09月20日 11时02分

公告 Citius Pharmaceuticals, Inc. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:Mazur Leonard L
公告日:2017-09-19, 内部交易人:Mazur Leonard L, 与发行人关系:Executive Chairman/, 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2017-09-15-06:00, SEC Accession No. 0001477932-17-004617, File:https://www.sec.gov/Archives/edgar/data/1506251/000147793217004617/0001477932-17-004617-index.htm $Citius Pharmaceuticals(CTXR)$
查看全文

Citius Pharmaceuticals(CTXR) 09月20日 11时02分

公告 Citius Pharmaceuticals, Inc. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:HOLUBIAK MYRON Z
公告日:2017-09-19, 内部交易人:HOLUBIAK MYRON Z, 与发行人关系:President and CEO/, 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2017-09-15-06:00, SEC Accession No. 0001477932-17-004615, File:https://www.sec.gov/Archives/edgar/data/1506251/000147793217004615/0001477932-17-004615-index.htm $Citius Pharmaceuticals(CTXR)$
查看全文

Citius Pharmaceuticals(CTXR) 09月20日 11时01分

公告 Citius Pharmaceuticals, Inc. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:Dutia Suren G
公告日:2017-09-19, 内部交易人:Dutia Suren G, 与发行人关系:, 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2017-09-15-06:00, SEC Accession No. 0001477932-17-004613, File:https://www.sec.gov/Archives/edgar/data/1506251/000147793217004613/0001477932-17-004613-index.htm $Citius Pharmaceuticals(CTXR)$
查看全文

Citius Pharmaceuticals(CTXR) 09月20日 11时01分

公告 Citius Pharmaceuticals, Inc. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:Kane William
公告日:2017-09-19, 内部交易人:Kane William, 与发行人关系:, 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2017-09-15-06:00, SEC Accession No. 0001477932-17-004611, File:https://www.sec.gov/Archives/edgar/data/1506251/000147793217004611/0001477932-17-004611-index.htm $Citius Pharmaceuticals(CTXR)$
查看全文

Citius Pharmaceuticals(CTXR) 09月20日 11时01分

公告 Citius Pharmaceuticals, Inc. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:Webb Carol
公告日:2017-09-19, 内部交易人:Webb Carol, 与发行人关系:, 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2017-09-15-06:00, SEC Accession No. 0001477932-17-004609, File:https://www.sec.gov/Archives/edgar/data/1506251/000147793217004609/0001477932-17-004609-index.htm $Citius Pharmaceuticals(CTXR)$
查看全文

Citius Pharmaceuticals(CTXR) 09月20日 11时01分

公告 Citius Pharmaceuticals, Inc. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:SAFIR HOWARD
公告日:2017-09-19, 内部交易人:SAFIR HOWARD, 与发行人关系:, 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2017-09-15-06:00, SEC Accession No. 0001477932-17-004607, File:https://www.sec.gov/Archives/edgar/data/1506251/000147793217004607/0001477932-17-004607-index.htm $Citius Pharmaceuticals(CTXR)$
查看全文

Citius Pharmaceuticals(CTXR) 09月20日 11时01分

公告 Citius Pharmaceuticals, Inc. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:Holuka Eugene Myron
公告日:2017-09-19, 内部交易人:Holuka Eugene Myron, 与发行人关系:, 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2017-09-15-06:00, SEC Accession No. 0001477932-17-004606, File:https://www.sec.gov/Archives/edgar/data/1506251/000147793217004606/0001477932-17-004606-index.htm $Citius Pharmaceuticals(CTXR)$
查看全文

Citius Pharmaceuticals(CTXR) 09月05日 23时20分

新闻 Citius Pharmaceuticals, Inc. Provides Phase 3 Update On Mino-Lok™ Clinical Trial Following FDA Meeting CRANFORD, N.J., Sept. 5, 2017 /PRNewswire/ -- Citius Pharmaceutic ......  url.vc.watch/AbT2
查看全文

Citius Pharmaceuticals(CTXR) 09月05日 21时31分

新闻 BRIEF-Citius Pharmaceuticals provides phase 3 update on Mino-Lok clinical trial following FDA meeting Sept 5 (Reuters) - Citius Pharmaceuticals Inc (CTXR.O) : * ......  url.vc.watch/AbyM
查看全文

Citius Pharmaceuticals(CTXR) 08月31日 02时11分

查看全文

Citius Pharmaceuticals(CTXR) 08月31日 02时10分

查看全文

Citius Pharmaceuticals(CTXR) 08月31日 02时10分

查看全文

Citius Pharmaceuticals(CTXR) 08月31日 02时10分

查看全文

Citius Pharmaceuticals(CTXR) 08月31日 02时10分

查看全文

Citius Pharmaceuticals(CTXR) 08月31日 02时10分

查看全文

Citius Pharmaceuticals(CTXR) 08月29日 10时59分

公告 Citius Pharmaceuticals, Inc. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:Mazur Leonard L
公告日:2017-08-28, 内部交易人:Mazur Leonard L, 与发行人关系:Executive Chairman/, 操作:买入,11000(股)Common Stock,均价$2.6800; 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2017-08-24-06:00, SEC Accession No. 0001477932-17-004226, File:https://www.sec.gov/Archives/edgar/data/1506251/000147793217004226/0001477932-17-004226-index.htm $Citius Pharmaceuticals(CTXR)$
查看全文

Citius Pharmaceuticals(CTXR) 08月15日 10时59分

查看全文

Citius Pharmaceuticals(CTXR) 08月15日 10时59分

查看全文

Citius Pharmaceuticals(CTXR) 08月11日 10时58分

公告 Citius Pharmaceuticals, Inc. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:Mazur Leonard L
公告日:2017-08-10, 内部交易人:Mazur Leonard L, 与发行人关系:Executive Chairman/, 操作:买入,421400(股)Common Stock,均价$4.1250; 操作:衍生证券转换(C),1547067(股)Common Stock,均价$3.09; 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2017-08-08-06:00, SEC Accession No. 0001477932-17-003817, File:https://www.sec.gov/Archives/edgar/data/1506251/000147793217003817/0001477932-17-003817-index.htm $Citius Pharmaceuticals(CTXR)$
查看全文
  • 首页 上一页 1 2 3 下一页 尾页  每页20条/共122
  • 友情链接:

    琥珀谷